Related Experiment Video
Updated: May 17, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.3K
Where Adults With Heart Failure Die: Insights From the CDC-WONDER Database.
Farman Ali1, Shaaf Ahmad2, Aman Ullah3
1Department of Internal Medicine, Corewell Health Dearborn Hospital, Dearborn, MI (F. Ali, T.J.B.).
Circulation. Heart Failure
|May 16, 2025
Summary
Deaths at home for heart failure (HF) patients nearly doubled between 1999 and 2023. This study analyzed HF mortality locations, revealing significant shifts and demographic disparities in end-of-life care settings.
Area of Science:
- Cardiology
- Public Health
- Gerontology
Background:
- Heart failure (HF) is a leading cause of mortality and significant healthcare expenditure.
- Integrating palliative care into HF management is increasingly emphasized.
- Data on end-of-life care locations for HF patients remain limited.
Purpose of the Study:
- To analyze the location and circumstances of death among adults with heart failure in the United States.
- To identify trends in where heart failure patients die over time.
- To examine demographic factors associated with death location in heart failure.
Main Methods:
- Analysis of mortality data from 1999-2023 for individuals aged 20+ with HF as the cause of death.
- Categorization of death locations: emergency room, hospice/nursing home, inpatient facility, or home.
- Multinomial logistic regression to assess associations between demographics and death location.
Main Results:
- Heart failure mortality rates declined until 2010, then increased by 2023.
- Deaths at home nearly doubled from 18.41% in 1999 to 33.47% in 2023.
- Hospice/nursing home deaths peaked in 2017 and declined by 2023; young adults showed higher inpatient deaths.
- Men, White individuals, and those in large metropolitan areas were more likely to die in medical facilities.
Conclusions:
- Significant shifts in end-of-life locations for heart failure patients observed, with a notable rise in home deaths.
- The recent decline in hospice/nursing home deaths warrants further investigation into potential barriers.
- Sociodemographic factors significantly influence disparities in heart failure death locations, requiring further research.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
01:22Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
01:26Heart Failure Drugs: Inotropic Agents
445
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445
01:26Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K